Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 2/20 | 0.69 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.69 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.50 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.48 |
| ▸ | OGA | O60502 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 9/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30824484 | 0.86 | HTR3A (0.73) | HTR3AHRH4HCRTR1HCRTR2HCAR2 | |
| SCHEMBL29648042 | 0.86 | HTR3A (0.73) | HTR3AHRH4HCRTR1HCRTR2HCAR2 | |
| SCHEMBL5508534 | 0.86 | HTR3A (0.73) | HTR3AHRH4HCRTR1HCRTR2HCAR2 | |
| SCHEMBL31691646 | 0.84 | HTR3A (0.71) | HTR3AHRH4HCRTR1HCRTR2HCAR2 | |
| SCHEMBL3776403 | 0.84 | HTR3A (0.71) | HTR3AHRH4HCRTR1HCRTR2HCAR2 | |
| SCHEMBL603314 | 0.81 | HTR3A (1.00) | HTR3AHRH4HCRTR1HCRTR2HCAR2 | |
| SCHEMBL2420211 | 0.81 | HTR3A (0.67) | HTR3AHRH4HCRTR1HCRTR2HCAR2 | |
| SCHEMBL1029333 | 0.81 | HTR3A (0.67) | HTR3AHRH4HCRTR1HCRTR2HCAR2 | |
| SCHEMBL29460463 | 0.81 | HTR3A (0.67) | HTR3AHRH4HCRTR1HCRTR2HCAR2 | |
| SCHEMBL27896727 | 0.81 | HTR3A (0.71) | HTR3AHRH4HCRTR1HCRTR2HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834015-B2 | treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, neurodegenerative diseases, retroviral infections, retinal damage, skin senescence and UV skin damage, and as chemosensitizers or radiosensitizers for cancer treatment | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2010-11-16 | — | — | US | disclosed |
| US-20090209523-A1 | Pyrrolo[1,2-A] Pyrazin-1(2H)-One and Pyrrolo[1,2-D][1,2,4]Triazin-1(2H)-One Derivatives as Inhibitors of Poly(Adp-Ribose)Polymerase (Parp) | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209523-A1 | Pyrrolo[1,2-A] Pyrazin-1(2H)-One and Pyrrolo[1,2-D][1,2,4]Triazin-1(2H)-One Derivatives as Inhibitors of Poly(Adp-Ribose)Polymerase (Parp) | PARP1, PARP2, PARP11 | HTR3A 2321/4885HRH4 3811/4885HCRTR1 2429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.